Mérieux and Shire funds back NeuroPhage in $12.4 million round for Alzheimer's
This article was originally published in Scrip
Executive Summary
NeuroPhage Pharmaceuticals, a privately held company based in Cambridge, Massachusetts, has been quietly advancing novel approaches to the treatment of neurodegenerative diseases, and now has gained attention by landing $12.4 million in new venture funding. It will use the funds to begin preparations for a Phase I trial of its lead candidate to treat Alzheimer's disease, NPT001, which disaggregates existing beta amyloid plaques.